Roles of the microRNA‑338‑3p/NOVA1 axis in retinoblastoma

Sun,Shoubin; Wang,Runze; Yi,Sisi; Li,Sijia; Wang,Lei; Wang,Jianwen

doi:10.3892/mmr.2021.12033

Roles of the microRNA‑338‑3p/NOVA1 axis in retinoblastoma

Authors:
- Shoubin Sun
- Runze Wang
- Sisi Yi
- Sijia Li
- Lei Wang
- Jianwen Wang
View Affiliations

Affiliations: Department of Ophthalmology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Ophthalmology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: March 22, 2021 https://doi.org/10.3892/mmr.2021.12033
Article Number: 394
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Retinoblastoma (RB) is an intraocular malignancy that mainly affects young children. Previous reports have demonstrated that mutations or the inactivation of the RB1 gene were the main cause of RB; however, disruption of the intracellular signaling pathways following deficiency of RB1 requires further investigation. Based on the Gene Expression Omnibus data and bioinformatics prediction, the present study aimed to investigate the microRNA (miR)‑338‑3p/neuro‑oncological ventral antigen 1 (NOVA1) axis in RB. Subsequently, overexpression and knockdown of miR‑338‑3p and NOVA1, respectively, were performed to study the role of miR‑338‑3p/NOVA1 in the progression of the RB cells. The results demonstrated that overexpression of miR‑338‑3p significantly inhibited cell proliferation, migration and invasion, and promoted apoptosis of the RB cells. Moreover, knockdown of NOVA1 showed similar results. A dual‑luciferase reporter assay and rescue experiments further confirmed the direct binding between miR‑338‑3p and NOVA1. Taken together, the results indicated that miR‑338‑3p acted as tumor suppressor by targeting the oncogene of NOVA1 in RB, which may serve as potential therapeutic targets in RB.

View Figures

View References

1	Lin FY and Chintagumpala MM: Neonatal retinoblastoma. Clin Perinatol. 48:53–70. 2021. View Article : Google Scholar : PubMed/NCBI
2	Lee C and Kim JK: Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications. J Cell Physiol. 236:2318–2332. 2021. View Article : Google Scholar : PubMed/NCBI
3	Fabian ID, Johnson KP, Stacey AW, Sagoo MS and Reddy MA: Focal laser treatment in addition to chemotherapy for retinoblastoma. Cochrane Database Syst Rev. 6:CD0123662017.PubMed/NCBI
4	Evangelatos G, Fragoulis GE, Koulouri V and Lambrou GI: MicroRNAs in rheumatoid arthritis: From pathogenesis to clinical impact. Autoimmun Rev. 18:1023912019. View Article : Google Scholar : PubMed/NCBI
5	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
6	Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, et al: Retinoblastoma. Nat Rev Dis Primers. 1:150212015. View Article : Google Scholar : PubMed/NCBI
7	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
8	Zeng R, Huang J, Sun Y and Luo J: Cell proliferation is induced in renal cell carcinoma through miR-92a-3p upregulation by targeting FBXW7. Oncol Lett. 19:3258–3268. 2020.PubMed/NCBI
9	Wang H, Li X, Li T, Wang L, Wu X, Liu J, Xu Y and Wei W: Multiple roles of microRNA-146a in immune responses and hepatocellular carcinoma. Oncol Lett. 18:5033–5042. 2019.PubMed/NCBI
10	Virga F, Quirico L, Cucinelli S, Mazzone M, Taverna D and Orso F: MicroRNA-mediated metabolic shaping of the tumor microenvironment. Cancers (Basel). 13:1272021. View Article : Google Scholar
11	Annese T, Tamma R, De Giorgis M and Ribatti D: microRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol. 10:5810072020. View Article : Google Scholar : PubMed/NCBI
12	Lu L, Wu M, Lu Y, Zhao Z, Liu T, Fu W and Li W: MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues. OncoTargets Ther. 12:7623–7636. 2019. View Article : Google Scholar
13	Chen Q, Guo SM, Huang HQ, Huang GP, Li Y, Li ZH, Huang R, Xiao L, Fan CR, Yuan Q, et al: Long noncoding RNA SBF2-AS1 contributes to the growth and metastatic phenotypes of NSCLC via regulating miR-338-3p/ADAM17 axis. Aging (Albany NY). 12:17902–17920. 2020. View Article : Google Scholar : PubMed/NCBI
14	Liu Z, Liu F, Wang F, Yang X and Guo W: CircZNF609 promotes cell proliferation, migration, invasion, and glycolysis in nasopharyngeal carcinoma through regulating HRAS via miR-338-3p. Mol Cell Biochem. 476:175–186. 2021. View Article : Google Scholar : PubMed/NCBI
15	Lu H, Zhang Q, Sun Y, Wu D and Liu L: LINC00689 induces gastric cancer progression via modulating the miR-338-3p/HOXA3 axis. J Gene Med. 22:e32752020. View Article : Google Scholar : PubMed/NCBI
16	Buckanovich RJ, Posner JB and Darnell RB: Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron. 11:657–672. 1993. View Article : Google Scholar : PubMed/NCBI
17	Gumina V, Colombrita C, Fallini C, Bossolasco P, Maraschi AM, Landers JE, Silani V and Ratti A: TDP-43 and NOVA-1 RNA-binding proteins as competitive splicing regulators of the schizophrenia-associated TNIK gene. Biochim Biophys Acta Gene Regul Mech. 1862:1944132019. View Article : Google Scholar : PubMed/NCBI
18	Zhang YA, Liu HN, Zhu JM, Zhang DY, Shen XZ and Liu TT: RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABAA Receptor-γ2. J Biomed Sci. 23:712016. View Article : Google Scholar : PubMed/NCBI
19	Bai S, Tian B, Li A, Yao Q, Zhang G and Li F: MicroRNA-125b promotes tumor growth and suppresses apoptosis by targeting DRAM2 in retinoblastoma. Eye (Lond). 30:1630–1638. 2016. View Article : Google Scholar : PubMed/NCBI
20	Jwala J, Vadlapatla RK, Vadlapudi AD, Boddu SH, Pal D and Mitra AK: Differential expression of folate receptor-alpha, sodium-dependent multivitamin transporter, and amino acid transporter (B (0, +)) in human retinoblastoma (Y-79) and retinal pigment epithelial (ARPE-19) cell lines. J Ocul Pharmacol Ther. 28:237–244. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang Q, Zhu Y, Zuo G, Chen X, Cheng J and Zhang S: LINC00858 promotes retinoblastoma cell proliferation, migration and invasion by inhibiting miR-3182. Exp Ther Med. 19:999–1005. 2020.PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Yu ACY, Chern YJ, Zhang P, Pasiliao CC, Rahman M, Chang G, Ren J and Tai IT: Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient-derived xenografts via activation of p53 and inhibition of AKT. Cancer Biol Ther. 22:112–123. 2021. View Article : Google Scholar : PubMed/NCBI
24	Francis JH, Richards AL, Mandelker DL, Berger MF, Walsh MF, Dunkel IJ, Donoghue MT and Abramson DH: Molecular changes in retinoblastoma beyond RB1: Findings from next-generation sequencing. Cancers (Basel). 13:1492021. View Article : Google Scholar
25	Guzman F, Fazeli Y, Khuu M, Salcido K, Singh S and Benavente CA: Retinoblastoma tumor suppressor protein roles in epigenetic regulation. Cancers (Basel). 12:28072020. View Article : Google Scholar
26	Zhang C and Wu S: microRNA-378a-3p restrains the proliferation of retinoblastoma cells but promotes apoptosis of retinoblastoma cells via inhibition of FOXG1. Invest Ophthalmol Vis Sci. 61:312020. View Article : Google Scholar
27	Kashiwa A, Aiba T, Makimoto H, Shimamoto K, Yamagata K, Kamakura T, Wada M, Miyamoto K, Inoue-Yamada Y, Ishibashi K, et al: Systematic evaluation of KCNQ1 variant using ACMG/AMP guidelines and risk stratification in long QT syndrome type 1. Circ Genom Precis Med. Sep 16–2020.(Epub ahead of print). doi: 10.1161/CIRCGEN.120.002926. View Article : Google Scholar : PubMed/NCBI
28	Wang Y and Qin H: miR-338-3p targets RAB23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 8:2564–2574. 2018.PubMed/NCBI
29	Wang L, Peng X, Lu X, Wei Q, Chen M and Liu L: Inhibition of hsa_circ_0001313 (circCCDC66) induction enhances the radio-sensitivity of colon cancer cells via tumor suppressor miR-338-3p: Effects of cicr_0001313 on colon cancer radio-sensitivity. Pathol Res Pract. 215:689–696. 2019. View Article : Google Scholar : PubMed/NCBI
30	Raizis AM, Racher HM, Foucal A, Dimaras H, Gallie BL and George PM: DNA hypermethylation/boundary control loss identified in retinoblastomas associated with genetic and epigenetic inactivation of the RB1 gene promoter. Epigenetics. Dec 1–2020.(Epub ahead of print). doi: 10.1080/15592294.2020.1834911. View Article : Google Scholar : PubMed/NCBI
31	Mehyar M, Mosallam M, Tbakhi A, Saab A, Sultan I, Deebajah R, Jaradat I, AlJabari R, Mohammad M, AlNawaiseh I, et al: Impact of RB1 gene mutation type in retinoblastoma patients on clinical presentation and management outcome. Hematol Oncol Stem Cell Ther. 13:152–159. 2020. View Article : Google Scholar : PubMed/NCBI
32	Sayed ME, Yuan L, Robin JD, Tedone E, Batten K, Dahlson N, Wright WE, Shay JW and Ludlow AT: NOVA1 directs PTBP1 to hTERT pre-mRNA and promotes telomerase activity in cancer cells. Oncogene. 38:2937–2952. 2019. View Article : Google Scholar : PubMed/NCBI
33	Villate O, Turatsinze JV, Mascali LG, Grieco FA, Nogueira TC, Cunha DA, Nardelli TR, Sammeth M, Salunkhe VA, Esguerra JL, et al: Nova1 is a master regulator of alternative splicing in pancreatic beta cells. Nucleic Acids Res. 42:11818–11830. 2014. View Article : Google Scholar : PubMed/NCBI
34	Trujillo CA, Rice ES, Schaefer NK, Chaim IA, Wheeler EC, Madrigal AA, Buchanan J, Preissl S, Wang A, Negraes PD, et al: Reintroduction of the archaic variant of NOVA1 in cortical organoids alters neurodevelopment. Science. 371:eaax25372021. View Article : Google Scholar : PubMed/NCBI
35	Kim DY, Choi JA, Koh JY and Yoon YH: Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma. J Exp Clin Cancer Res. 35:1712016. View Article : Google Scholar : PubMed/NCBI
36	Kulkarni AD, van Ginkel PR, Darjatmoko SR, Lindstrom MJ and Albert DM: Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. Br J Ophthalmol. 93:1105–1108. 2009. View Article : Google Scholar : PubMed/NCBI
37	Liu XM, Li XF and Li JC: MiR-146a functions as a potential tumor suppressor in retinoblastoma by negatively regulate neuro-oncological ventral antigen-1. Kaohsiung J Med Sci. Dec 19–2020.(Epub ahead of print). doi: 10.1002/kjm2.12337. View Article : Google Scholar
38	Xu L, Zhu S, Tang A and Liu W: LncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/β-catenin signaling pathway. Inflamm Res. 70:217–227. 2021. View Article : Google Scholar : PubMed/NCBI
39	Liu H, Yuan HF, Xu D, Chen KJ, Tan N and Zheng QJ: Circular RNA circ_0000034 upregulates STX17 level to promote human retinoblastoma development via inhibiting miR-361-3p. Eur Rev Med Pharmacol Sci. 24:12080–12092. 2020.PubMed/NCBI